Transgenomic EGFR C797S Mutation Detection Assay
Transgenomic has launched its EGFR C797S Mutation Detection assay. The assay is based on the company's ICE COLD-PCR technology and detects the presence of the EGFR C797S mutation that is associated with resistance to new third-generation tyrosine kinase inhibitor therapies in development for non-small cell lung cancer. The high sensitivity of Transgenomic's ICP technology makes it possible to run the new assay using either tissue, blood, or serum samples, the company said. The test is currently only available for research use through Transgenomic's Biomarker Discovery Services group, and is expected to be available for clinical use through the company's oncology CLIA laboratory in Omaha, Nebraska later this year.